Stockscreener 앱 받기
38.08
0.03%
1.1006
시간 외 거래:
39.00
0.9194
+2.41%
전일 마감가:
$36.98
열려 있는:
$36.74
하루 거래량:
30,019
Relative Volume:
66.00
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
74.67
EPS:
0.51
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.71%
6개월 성능:
+29.47%
1년 성능:
+0.79%
1일 변동 폭
$35.95
$40.38
1주일 범위
$35.95
$40.38
52주 변동 폭
$35.95
$40.38
Defiance Daily Target 2 X Long Lmnd Etf Stock (LMNX) Company Profile
명칭
Defiance Daily Target 2 X Long Lmnd Etf
전화
-
주소
-
LMNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LMNX
Defiance Daily Target 2 X Long Lmnd Etf
|
38.08 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
337.56 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
685.69 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
689.11 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
260.19 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
625.48 | 124.43B | 0 | 0 | 0 | 0.00 |
Defiance Daily Target 2 X Long Lmnd Etf Stock (LMNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-18 | 재개 | Piper Sandler | Overweight |
| 2019-09-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-12 | 개시 | Avondale | Mkt Outperform |
| 2016-08-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2015-08-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2013-11-05 | 재확인 | UBS | Neutral |
| 2013-07-30 | 다운그레이드 | UBS | Buy → Neutral |
| 2012-08-23 | 업그레이드 | UBS | Neutral → Buy |
| 2012-07-31 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2012-05-01 | 재확인 | UBS | Neutral |
| 2010-03-12 | 개시 | Jefferies & Co | Buy |
| 2009-11-18 | 개시 | William Blair | Mkt Perform |
| 2009-05-08 | 재확인 | Wedbush Morgan | Buy |
| 2009-04-14 | 개시 | Piper Jaffray | Neutral |
| 2008-12-12 | 다운그레이드 | Leerink Swann | Outperform → Mkt Perform |
| 2008-10-16 | 개시 | UBS | Neutral |
| 2008-10-10 | 개시 | Cowen & Co | Neutral |
| 2008-08-08 | 재확인 | Canaccord Adams | Buy |
모두보기
Defiance Daily Target 2 X Long Lmnd Etf 주식(LMNX)의 최신 뉴스
Defiance Daily Target 2X Long LMND ETF Holdings List (NASDAQ:LMNX) - MarketBeat
Best Stocks Under $50 Right Now - Benzinga
US Stock Market top gainers and losers on November 5: MMTec, Inc. sees over 600% jump, ETHZilla Corporatio - The Economic Times
U.S. Equity ETF Tracker | Cryptocurrency concepts rebound across the board, with the 2x Long IREN ETF surging 28%; gold strengthens again, driving the 2x Long Gold Miners ETF up over 7%; Super Micro Computer's earnings miss expectations, pushing the - 富途牛牛
Defiance Daily Target 2x Long LMND ETF (Nasdaq:LMNX) Stock Quote - Markets Financial Content
U.S. Equity ETF Tracker | All three major indices hit new highs, with the triple-leveraged Nasdaq ETF surging over 5%; Qualcomm's two-times leveraged ETF soared 22% amid its push into AI data centers to challenge NVIDIA; Spot gold fell below the $4,000 m - 富途牛牛
The Lethbridge HeraldNews and Sports from around Lethbridge - Markets Financial Content
Defiance debuts 2x leveraged Lemonade tracker - Structured Retail Products
KraneShares Makes Bold Bet On JD.com With 2X Leveraged ETF During US-China Trade Tensions - inkl
Defiance Doubles Down On Lemonade With New 2X ETF For Bold Traders - Sahm
5x Tesla, Bitcoin, Strategy ETFs In Doubt As SEC Signals Uncertainty During Shutdown - inkl
Attachment - GlobeNewswire
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Singapore
US ETF launches from 9th to 16th October, 2025 - ETF Express
Defiance Launches LMNX: The First 2X Long ETF for Lemonade, Inc. - GlobeNewswire
Multiplex Assay Market to Witness Massive Growth by 2032 | Luminex Corporation, Thermo Fisher Scientific, Inc. - openPR.com
Invitrogen Renews Supply Pact with Luminex - Photonics Spectra
Luminex and Life Technologies Combine Forces on NIST DNA Project | News & Features | Sep 2000 - Photonics Spectra
Prime Mining: Big Grades, Big Vision in Mexico's Gold Belt - The Globe and Mail
Brompton Funds: BGIEInvesting in What the World Can’t Do Without - The Globe and Mail
xMAP Connect Virtual - Labroots
PTAB Axes Most Claims In Signify Lighting Patent - Law360
Flow Cytometry Market Size, Share, and Growth Status; Emerging - openPR.com
2023 Virtual xMAP® Connect - Labroots
Proteomics Market Growth and Future Scope 2025-2032 | Thermo - openPR.com
Respiratory Pathogen Testing Market Set for Significant - openPR.com
Herpes Markers Testing Market Outlook 2024 to 2034: Growth - openPR.com
Transcript : Luminex CorporationSpecial Call - MarketScreener
How the Flow Cytometry Market Will Evolve by 2032Growth, - openPR.com
Flow Cytometry Market Exclusive Report with Detailed Analysis - openPR.com
Weekly ETF Industry Recap: U.S., Europe, and Canada Highlights – July 7-July 11, 2025 - Trackinsight
Microspheres Market Set to Soar: Innovations in Medical, - openPR.com
Global Multiplex Assay Market to Hit USD 8.84 Billion by - GlobeNewswire
US NYSE/NASD Stock Directory - Minichart
Proteomics Market May See a Big Move: GE Healthcare, Luminex Corporation, Bruker Corporation - newstrail.com
Meet the Florida Board of Trustees - The Nature Conservancy
Plus Therapeutics appoints Russell Bradley as president, CNSide - TipRanks
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary - GlobeNewswire
Director Review Clarified Co-Defendant IPR Challenge Rights in 2024 - IPWatchdog.com
Top ETF Losers: ETFs posting the largest losses today - Yahoo! Finance Canada
Markets: World indices, futures, bonds, currencies, stocks and ETFs - Yahoo! Finance UK
Top ETF gains: ETFs posting the highest gains today - Yahoo! Finance UK
Top ETF Gains: ETFs posting the highest gains today - Yahoo! Finance Canada
Examining Vidal's Guidance On PTAB Section 315 Time Bar - Law360
The role of imaging flow cytometry in defining cancer immunotherapies - Nature
Small particle analysis using high sensitivity flow cytometry - Nature
Vidal Lays Out Reasoning For Reviving Lighting IP Challenge - Law360
Stereotaxis appoints Nachum Shamir to board of directors - Medical Buyer
[Latest] Global Cardiac Troponin Market Size/Share Worth USD 4.2 Billion by 2033 at a 12.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - Yahoo Finance
Diagnosis and Management of Bloodstream Infections With Rapid, Multiplexed Molecular Assays - Frontiers
Myriad RBM President Discusses Ultra-Sensitive Immunoassays and Their Importance in Pharmacology - SelectScience
Defiance Daily Target 2 X Long Lmnd Etf (LMNX) 재무 분석
Defiance Daily Target 2 X Long Lmnd Etf (LMNX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.11%
0.45%
자본화:
|
볼륨(24시간):